13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001583977
Total reported value
$2.0B
$2.0B
48 檔
45.8%
In Q4 2024, Cormorant Asset Management, LP's U.S. equity holdings reached a combined market value of $2.0B, distributed across 48 disclosed stock positions.
Cormorant Asset Management, LP executed strategic sector rebalancing during Q4 2024, establishing 8 new positions while fully exiting 5 holdings and trimming 11 positions.
In terms of portfolio concentration, the top 5 core holdings (including MLTX, PRAX, JANX) accounted for 45.8% of total reported equity market value during Q4 2024.
Top New Position Initiated
DRUG
市值: $38.2M
Top Position Liquidated / Trimmed
LONGBOARD PHARMACEUTICALS IN
前期市值: $93.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 25.26% | -0.99% | — | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 7.16% | -3.35% | +94.62% | |
| 3 | JANX | Janux Therapeutics Inc | Stock-Other | 6.17% | — | +100.00% | |
| 4 | ACLXGBX | Arcellx Inc | Stock-Other | 5.48% | — | +4.00% | |
| 5 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.00% | +0.07% | — | |
| 6 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 4.59% | -0.66% | +31.58% | |
| 7 | EYPT | Eyepoint Inc | Stock-Other | 3.41% | -0.22% | — | |
| 8 | RAPP | Rapport Therapeutics Inc | Stock-Other | 2.87% | +1.02% | — | |
| 9 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.81% | -0.22% | -9.09% | |
| 10 | INSM | Insmed Inc | Stock-Healthcare | 2.46% | -1.15% | +30.00% | |
| 11 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.41% | -1.07% | -13.90% | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.36% | -2.09% | EXIT | |
| 13 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.10% | -0.64% | — | |
| 14 | PCVX | Vaxcyte Inc | Stock-Other | 1.91% | -0.14% | -57.50% | |
| 15 | ✓ | Merus N V | Stock-Other | 1.71% | — | — | |
| 16 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.68% | — | — | |
| 17 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.68% | — | — | |
| 18 | PHVS | Pharvaris N.V. | Stock-Other | 1.54% | -0.09% | — | |
| 19 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.54% | +0.02% | — | |
| 20 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.52% | -0.47% | — | |
| 21 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.51% | -0.42% | EXIT | |
| 22 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.40% | -0.29% | -21.51% | |
| 23 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.23% | — | — | |
| 24 | CGON | Cg Oncology Inc | Stock-Other | 1.22% | — | -20.51% | |
| 25 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.94% | — | — | |
| 26 | ALMS | Alumis Inc | Stock-Other | 0.93% | +0.37% | — | |
| 27 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.87% | — | — | |
| 28 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.86% | — | — | |
| 29 | ABVX | Abivax Sa-adr | Stock-Other | 0.86% | +0.36% | — | |
| 30 | ✓ | Engene Holdings Inc | Stock-Other | 0.85% | — | +132.36% | |
| 31 | BIOA | Bioage Labs Inc | Stock-Other | 0.84% | +0.46% | +61.37% | |
| 32 | BMEA | Biomea Fusion Inc | Stock-Other | 0.76% | — | — | |
| 33 | MBX | Mbx Biosciences Inc | Stock-Other | 0.71% | -0.12% | — | |
| 34 | SEPN | Septerna Inc | Stock-Other | 0.70% | — | — | |
| 35 | IBRX | Immunitybio Inc | Stock-Healthcare | 0.42% | — | — | |
| 36 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.31% | +0.39% | NEW | |
| 37 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.29% | — | — | |
| 38 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 39 | KALAEUR | Kala Bio Inc | Stock-Other | 0.23% | — | — | |
| 40 | GHRS | GH Research PLC | Stock-Other | 0.23% | — | — | |
| 41 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 0.18% | — | -70.69% | |
| 42 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.18% | — | -80.65% | |
| 43 | OMER | Omeros CORP | Stock-Other | 0.16% | — | — | |
| 44 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.15% | — | -40.50% | |
| 45 | BHVN | Biohaven Ltd. | Stock-Other | 0.11% | +1.24% | -86.18% | |
| 46 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 47 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.06% | — | — | |
| 48 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.02% | — | -59.74% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | +4.5% | +94.62% | Add |
| 2 | JANX | Janux Therapeutics Inc | +3.6% | +100.00% | Add |
| 3 | MLTX | Moonlake Immunotherapeutics | +2.6% | — | Unchanged |
| 4 | NAMS | NewAmsterdam Pharma Company N.V. | +2.4% | +31.58% | Add |
| 5 | DRUG | Bright Minds Biosciences Inc | +2.1% | NEW | New buy |
| 6 | OKUR | Onkure Therapeutics Inc-a | +0.9% | NEW | New buy |
| 7 | SEPN | Septerna Inc | +0.7% | NEW | New buy |
| 8 | TARS | Tarsus Pharmaceuticals Inc | +0.7% | — | Unchanged |
| 9 | INSM | Insmed Inc | +0.5% | +30.00% | Add |
| 10 | ✓ | Engene Holdings Inc | +0.5% | +132.36% | Add |
| 11 | IBRX | Immunitybio Inc | +0.4% | NEW | New buy |
| 12 | ELVN | Enliven Therapeutics Inc | +0.3% | NEW | New buy |
| 13 | SPRY | Ars Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 14 | ARQT | Arcutis Biotherapeutics Inc | +0.3% | -21.51% | Trim |
| 15 | KALAEUR | Kala Bio Inc | +0.2% | NEW | New buy |
| 16 | 260 | Centessa Pharmaceuticals-adr | +0.2% | — | Unchanged |
| 17 | EWTX | Edgewise Therapeutics Inc | +0.2% | — | Unchanged |
| 18 | OMER | Omeros CORP | +0.2% | NEW | New buy |
| 19 | AVBP | Arrivent Biopharma Inc | +0.1% | — | Unchanged |
| 20 | VYNE | Vyne Therapeutics Inc | +0.1% | — | Unchanged |
| 21 | RYTM | Rhythm Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 22 | PHVS | Pharvaris N.V. | +0.1% | — | Unchanged |
| 23 | ✓ | Helix Acquisition CORP Ii | +0.1% | — | Unchanged |
| 24 | ✓ | Verve Therapeutics Inc | 0% | — | Unchanged |
| 25 | GHRS | GH Research PLC | 0% | — | Unchanged |
| 26 | ARTV | Artiva Biotherapeutics Inc | 0% | — | Unchanged |
| 27 | ✓ | Rapt Therapeutics Inc | 0% | -59.74% | Trim |
| 28 | ACLXGBX | Arcellx Inc | -0.1% | +4.00% | Add |
| 29 | BBIO | Bridgebio Pharma Inc | -0.1% | -13.90% | Trim |
| 30 | EYPT | Eyepoint Inc | -0.1% | — | Unchanged |
| 31 | STOK | Stoke Therapeutics Inc | -0.1% | -40.50% | Trim |
| 32 | CRNX | Crinetics Pharmaceuticals In | -0.2% | -9.09% | Trim |
| 33 | CRGX | Cargo Therapeutics Inc | -0.2% | — | Unchanged |
| 34 | NGNE | Neurogene Inc | -0.2% | EXIT | Sold out |
| 35 | ✓ | Merus N V | -0.3% | — | Unchanged |
| 36 | MBX | Mbx Biosciences Inc | -0.3% | — | Unchanged |
| 37 | ALMS | Alumis Inc | -0.3% | — | Unchanged |
| 38 | RAPP | Rapport Therapeutics Inc | -0.3% | — | Unchanged |
| 39 | SLN | Silence Therapeutics Plc-adr | -0.4% | EXIT | Sold out |
| 40 | AXSM | Axsome Therapeutics Inc | -0.4% | -18.75% | Trim |
| 41 | ABVX | Abivax Sa-adr | -0.4% | — | Unchanged |
| 42 | KRRO | Korro Bio Inc | -0.5% | EXIT | Sold out |
| 43 | ANAB | Anaptysbio Inc | -0.6% | EXIT | Sold out |
| 44 | CGON | Cg Oncology Inc | -0.7% | -20.51% | Trim |
| 45 | YMABUSD | Y-mabs Therapeutics Inc | -0.8% | -70.69% | Trim |
| 46 | URGN | UroGen Pharma Ltd. | -0.9% | -80.65% | Trim |
| 47 | RNAGBP | Avidity Biosciences Inc | -0.9% | — | Unchanged |
| 48 | BIOA | Bioage Labs Inc | -1% | +61.37% | Add |
| 49 | BHVN | Biohaven Ltd. | -1% | -86.18% | Trim |
| 50 | CRBP | Corbus Pharmaceuticals Holdi | -1.1% | — | Unchanged |
According to official SEC Form 13F filings, Cormorant Asset Management, LP reported a total U.S. public equity portfolio value of $2.0B across 48 disclosed positions in Q4 2024.
During Q4 2024, Cormorant Asset Management, LP's top holdings by market value included MLTX (25.3%)、PRAX (7.2%)、JANX (6.2%). The largest single position, MLTX, represented 25.3% of total portfolio value.
In Q4 2024, Cormorant Asset Management, LP made 31 total portfolio adjustments, initiating 8 new buys, adding to 7 positions, trimming 11 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.